Assessment of quality of life in chronic hepatitis C: Effect of treatment;Évaluation de la qualité de vie au cours de l'hépatite chronique C: Influence du traitement

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 12, 2003, Pages 1084-1090

  Desmorat, Hervé ^a   Combis, Jean Marc ^a   Pradat, Pierre ^b  

^a Ctr Invest Malad Foie/Voies B   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC HEPATITIS; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; QUALITY OF LIFE; SELF REPORT; TREATMENT OUTCOME; CLINICAL TRIAL; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; VIROLOGY;

ADULT; FEMALE; HEALTH STATUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 1442309052     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Piche T, Tran A. Fatigue au cours de l'hépatite chronique C: un symptôme à ne pas négliger. Gastroenterol Clin Biol 2001;25:1059-60.
2. Fisk JD, Pontrefact A, Ritvo PF, Ross L, Haase DA, Marrie TJ, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Can J Neurol Sci 1994;21:9-14.
3. Schipper H, Clinch J, Powell V. Definitions and conceptual issues. In: Spilker B. Quality of life assessments in clinical trials. Raven Press, New-York, 1990;2:11-24.
4. Spilker B. Quality of life assessments in clinical trials. Raven Press. New-York, 1990.
5. Walker SR, Rosser RM. Quality of life assessment: key issues in the 1990s. Dordrecht/Boston/London: Kluwer Academic Publishers, 1993.
6. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002;324:1417-21.
7. Sanders, C, Egger M, Donovan, J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ 1998;317:1191-4.
8. Ware J, Sherbourne C. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
9. Leplège A, Mesbah M, Marquis P. Analyse préliminaire des propriétés psychométriques de la version française d'un questionnaire international de mesure de la qualité de vie: le MOS SF-36 (version 1.1). Rev Epidemiol Sante Publique 1995;43:371-9.
10. Raymond JM. Pourquoi et comment mener des études de qualité de vie en gastroentérologie? Gastroenterol Clin Biol 1996;20:1067-70.
11. French Consensus Conference, Paris, February 2002. Treatment of Hepatitis C. Recommendations. Med Sciences 2002;18:375-82.
12. International consensus conference on hepatitis C. Conclusions. Organized under the auspices of the European Association for the Study of the Liver (EASL). Ann Med Interne 1999;150:449-53.
13. Carithers R, Sugano D, Bayliss M. Health assessment for chronic HCV infection. Results of quality of life. Dig Dis Sci 1996;41(suppl.):75S-80S.
14. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol 2001;32:413-17.
15. Bayliss M, Gandek B, Bungay K, Sugano D, Hsu MA, Ware J. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998;7:39-55.
16. Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998:27:209-12.
17. Owens D. In the eye of the beholder: Assessment of health-related quality of life. Hepatology 1998;27:292-3.
18. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 1994;16:334-43.
19. Remy AJ, Daurès JP, Tanguy G, Khemissa F, Chevrier M, Lezotre PL, et al. Mesure de la qualité de vie chez les malades ayant une hépatite chronique virale C: validation d'un indicateur général et d'un indicateur spécifique. Gastroenterol Clin Biol 1999;23:1296-309.
20. Foster G. Hepatitis C virus infection: quality of life and side effects of treatment. J Hepatol 1999;31(Suppl. 1):250-4.
21. Bonkovsky H, Woolley JM and the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-70.
22. Neary MP, Cort S, Bayliss MS, Ware JE. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999;19(Suppl. 1):77-85.
23. Ware J, Bayliss M, Mannocchia M, Davis G, and the International Hepatitis Interventional Therapy Group. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. Hepatology 1999:30:550-5.
24. McHorney CA, Ware JE. Lu JFR, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumtions and reliability across diverse patient groups. Medical Care 1994;32:40-66.
25. McHorney CA, Ware JE. Raczek AE. The MOS 36-item short-form health status survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993;31:247-63.
26. Brazier JE, Harper R, Jones NMB, O'Cathain A, Thomas KJ. Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-4.
27. Garratt AM, Ruta DA. Abdalla MI. Buckingham JK, Russell IT. The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993;306:1440-4.
28. Leplège A. Le questionnaire MOS SF-36. Manuel d'utilisateur et guide d'interprétation des scores. Eds Estem. ISBN 2 84371 118 5.
29. Thursz M, Rahman R, Murphy C, Robinson NJ, Rosenberg DM, Thomas H, et al. Health related quality of life in patients with chronic hepatitis C in the UK. Antiviral therapy 2000;5(Suppl. 1):C60.
30. Koff RS. Impaired health-related quality of life in chronic hepatitis C: the how but not the why. Hepatology 1999;29:277-9.
31. Fontana RJ, Moyer CA, Sonnad SS, Lok ASF, Sneed-Pee N, Walsh J, et al. Co-morbidities and quality of life in patients with interferon refractory chronic hepatits C. Am J Gastroenterol 2001;96:170-8.
32. Kowdley KV, Dwight MM, Larson AM, Russo J, Katon WJ. Depressive disorders are a major cause of functional impairment among patients with chronic hepatits C (abstract). Hepatology 1998;28:A569.
33. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations in patients with chronic hepatitis C. Arthritis Rheum 1999;42:2204-12.
34. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-9.
35. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002;37:349-54.
36. Forton D, Thomas H, Murphy C, Allsop J, Foster G, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-9.
37. Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatits C virus on quality of life. Hepatology 1999;30:1299-301.
38. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D, and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997;26:485-90.
39. Fontana R, Hussain K, Schwartz S, Moyer C, Su G, Lok A. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002;36:401-7.
40. McHutchison J, Ware J, Bayliss M, Pianko S, Albrecht J, Cort S, et al. and the Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-7.
41. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998;37:93-7.
42. Roudot-Thoraval F, Abergel A, Allaert F, Bourlière M, Desmorat H, Fagnani F, et al. Hépavir, première étude observationnelle d'une cohorte de malades traités par interféron alpha-2a en monothérapie. Evaluation de l'asthénie et de ses répercussions sociales. Gastroenterol Clin Biol 2001;25:1061-6.
43. Bianchi G, Loguercio C, Sgarbi D, Abbiati R, Chen CH, Di Pierro M. et al. Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Digest Liver Dis 2000;32:398-405.
44. Feagan BG, Trépo C, Lindsay KL, Niederau C, Wong CJ, Weng CSW, et al. The impact of pegylated interferon alfa-2b on health quality of life in chronic hepatitis C patients (abstract). Hepatology 2000;32:307A.
45. Rasenack J, Zeuzem S, Feinman V, Heathcote EJ, Manns M, Yoshida E, et al. Therapy with pegylated (40 KDA) interferon alfa 2a (Pegasys) significantly enhances quality of life compared with standard interferon alfa 2a (Roferon A) in patients with chronic hepatitis C (abstract). Hepatology 2000;32:307A.
46. Rothstein KD, Perillo RP, Imperial J, Alam I, Palmer M, Pockros PJ, et al. Efficacity, quality of life, safety and tolerability in patients with chronic hepatitis C treated with PEG (40 KDA) IFN alfa 2a (PEGASYS) or standard interferon alfa 2b-ribavirin (rebetron) combination therapy (abstract). Gastroenterology 2001;120:A85.
47. Hassanein TI, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, et al. Treatment with 40 KDA Peginterferon alfa 2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa 2b plus ribavirin (abstract). Hepatology 2001;34:243A.
48. Bernstein D, Kleinman L, Barker C, Revicki D, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-8.